EP1567506A4 - CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR - Google Patents

CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR

Info

Publication number
EP1567506A4
EP1567506A4 EP03768789A EP03768789A EP1567506A4 EP 1567506 A4 EP1567506 A4 EP 1567506A4 EP 03768789 A EP03768789 A EP 03768789A EP 03768789 A EP03768789 A EP 03768789A EP 1567506 A4 EP1567506 A4 EP 1567506A4
Authority
EP
European Patent Office
Prior art keywords
cyanoamidines
cyanoguanidines
erbb2
egfr inhibitors
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03768789A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1567506A2 (en
Inventor
Eli Wallace
George Topalov
Qian Zhao
Joseph P Lyssikatos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of EP1567506A2 publication Critical patent/EP1567506A2/en
Publication of EP1567506A4 publication Critical patent/EP1567506A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP03768789A 2002-11-20 2003-11-10 CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR Withdrawn EP1567506A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42754402P 2002-11-20 2002-11-20
US427544P 2002-11-20
PCT/US2003/035670 WO2004046101A2 (en) 2002-11-20 2003-11-10 Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors

Publications (2)

Publication Number Publication Date
EP1567506A2 EP1567506A2 (en) 2005-08-31
EP1567506A4 true EP1567506A4 (en) 2007-06-20

Family

ID=32326558

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03768789A Withdrawn EP1567506A4 (en) 2002-11-20 2003-11-10 CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR

Country Status (6)

Country Link
EP (1) EP1567506A4 (OSRAM)
JP (1) JP4611745B2 (OSRAM)
AU (1) AU2003291394B2 (OSRAM)
CA (1) CA2506503A1 (OSRAM)
NZ (1) NZ540092A (OSRAM)
WO (1) WO2004046101A2 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
CN108285421A (zh) * 2018-01-26 2018-07-17 黑龙江鑫创生物科技开发有限公司 一种微通道反应器合成拉帕替尼中间体的方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562319B2 (en) 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
SG135193A1 (en) * 2003-08-18 2007-09-28 Pfizer Prod Inc Dosing schedule for erbb2 anticancer agents
JP2007505101A (ja) * 2003-09-11 2007-03-08 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム 放射性標識されたアニリノキナゾリン型化合物ならびに放射線画像化および放射線治療におけるその使用
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
EP1789055A4 (en) 2004-09-15 2009-11-11 Janssen Pharmaceutica Nv INHIBITORS OF THIAZOLOPYRIDINE KINASE
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors
DE102006012251A1 (de) * 2006-03-15 2007-11-08 Grünenthal GmbH Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
US7851623B2 (en) 2006-11-02 2010-12-14 Astrazeneca Ab Chemical process
EA018716B1 (ru) 2007-10-29 2013-10-30 Натко Фарма Лимитед Новые 4-(тетразол-5-ил) хиназолиновые производные в качестве противораковых средств
EP2448409A4 (en) 2009-07-02 2013-04-10 Newgen Therapeutics Inc PHOSPHOROUS CHINAZOLIN COMPOUNDS AND METHOD OF USE THEREOF
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
NZ719185A (en) 2013-11-01 2017-11-24 Kala Pharmaceuticals Inc Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2017122205A1 (en) 2016-01-13 2017-07-20 Hadasit Medical Research Services And Development Ltd. Radiolabeled erlotinib analogs and uses thereof
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018048747A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP4069252B1 (en) * 2019-12-02 2025-12-10 Academia Sinica Pdia4 inhibitors and use thereof for inhibiting ss-cell pathogenesis and treating diabetes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1067123A1 (en) * 1998-03-31 2001-01-10 Kyowa Hakko Kogyo Co., Ltd. Nitrogenous heterocyclic compounds
EP1110953A1 (en) * 1995-03-30 2001-06-27 Pfizer Inc. Quinazoline derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
PL194689B1 (pl) * 1996-02-13 2007-06-29 Astrazeneca Uk Ltd Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
GB2345486A (en) 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
HUP0301120A2 (hu) 2000-06-22 2003-08-28 Pfizer Products Inc. Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1110953A1 (en) * 1995-03-30 2001-06-27 Pfizer Inc. Quinazoline derivatives
EP1067123A1 (en) * 1998-03-31 2001-01-10 Kyowa Hakko Kogyo Co., Ltd. Nitrogenous heterocyclic compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO2004046101A2 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9827248B2 (en) 2013-02-15 2017-11-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9877970B2 (en) 2013-02-15 2018-01-30 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US10398703B2 (en) 2013-02-15 2019-09-03 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US10966987B2 (en) 2013-02-15 2021-04-06 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
CN108285421A (zh) * 2018-01-26 2018-07-17 黑龙江鑫创生物科技开发有限公司 一种微通道反应器合成拉帕替尼中间体的方法

Also Published As

Publication number Publication date
WO2004046101A2 (en) 2004-06-03
AU2003291394B2 (en) 2009-06-25
EP1567506A2 (en) 2005-08-31
JP2006508979A (ja) 2006-03-16
NZ540092A (en) 2007-06-29
CA2506503A1 (en) 2004-06-03
AU2003291394A1 (en) 2004-06-15
JP4611745B2 (ja) 2011-01-12
WO2004046101A3 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
EP1567506A4 (en) CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR
IL165046A0 (en) Pyrimidinone compounds, compositions and methods
IL169112A0 (en) Phosphonooxy quinazoline derivatives and their pharmaceuitical use
AU2003259749A1 (en) 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
ZA200500680B (en) Quinoline derivatives and their use as mycrobacterial inhibitors
AU2003262747A8 (en) Compounds, compositions, and methods
AU2003236527A8 (en) Compounds, compositions, and methods
AU2003265242A8 (en) Compounds, compositions, and methods
AU2003270015A8 (en) Compounds, compositions, and methods
EP1575495A4 (en) COMPOUNDS AND METHODS
AU2003275955A8 (en) Scheme for spreading and facilitating remote e-services
AU2003299612A8 (en) Compounds, compositions and methods
IL164581A0 (en) Compounds, compositions and methods
EP1537089A4 (en) CONNECTIONS, COMPOSITIONS AND PROCEDURES
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
AU2003277079A8 (en) Compounds, compositions, and methods
AU2003290507A8 (en) Compounds, compositions and methods
IL167936A0 (en) Compounds, compositions,and methods
GB0220385D0 (en) Compound and process
ZA200409691B (en) Heterotricyclyl 6-alkylidene-penems as ß-lactamase inhibitors
AU2003300031A8 (en) Compounds, compositions, and methods
AU2003267169A8 (en) Compounds, compositions and methods
GB0300179D0 (en) Mouse
HK1080861A (en) Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
GB0215867D0 (en) Novel method and compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050614

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1080861

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20070521

17Q First examination report despatched

Effective date: 20081119

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110218

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1080861

Country of ref document: HK